# CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

> **NCT05672147** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 27 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Recurrent Adult Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** Anti-CD33 CAR T-cells
- **PROCEDURE:** Lymphodepletion Therapy

## Key facts

- **NCT ID:** NCT05672147
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-07
- **Primary completion:** 2028-09-03
- **Final completion:** 2028-09-03
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05672147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05672147, "CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05672147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*